The China Vaccine Market is Expected to Surpass $12.16 Billion by 2027

News provided by

Jan 31, 2023, 16:00 ET

DUBLIN, Jan. 31, 2023 /PRNewswire/ -- The "China Vaccine Market, Size, Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

This report provides a complete analysis of China Vaccine Market, the market will surpass US$ 12.16 Billion by 2027 at a CAGR of 11.97 Percent according to the publisher.

Annually in China, approx. 700 million vaccine doses are produced; China is one of the world's largest producers of vaccines. As a result, China has drawn significant attention to the vaccine industry to play a representative role. In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.

Category 1 & 2 Vaccines in China

In China, Vaccines are available through the government's Expanded Program on Immunization (EPI) at no charge for aged 14 years of children. These government-purchased vaccines are called Category 1 under the Regulations on the Administration of Vaccines and Vaccination.

In contrast, private-sector also known as Category 2 vaccines, such as rabies vaccine, influenza vaccine (InfV), and Haemophilus influenza type b vaccine (Hib), are available but are usually paid for out-of-pocket, as they are included in neither the EPI system nor government health insurance. According to our research findings, the China Vaccine market was US$ 6.91 Billion in 2022.

Disease Type: Pneumococcal, Meningococcal Meningitis, and DTP Vaccines Controls Significant Portion of China Vaccines Industry

Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market. The vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others.

In Aug 2021, China formally revised its laws to allow parents to have up to three children to boost the birth rate. In part, thanks to the loosening of the second-child policy in China, the number is expected to increase. China's vaccine industry has always been more petite and less mature than it's US, European, or Indian counterparts.

However, over the past decades, it has rapidly grown to become one of the only developing countries able to manufacture and supply most vaccines used in its domestic immunization program.

Product Insight: PCV13 has Highest Share in the Chinese Vaccine Industry

In terms of products, the Products included in this report are as follows: MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, and PPV23. PCV13 holds the maximum share of the China vaccine market. Therefore, it is predicted that PCV13 will also maintain its top place during the forecasting period.

In addition, China is the most prominent vaccine consumer in the world. As a result, Chinese residents have become much more aware of preventive health care due to its impact, which has also driven the vaccination rate.

Key Company Insights

The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

In addition, the R&D, clinical, and commercialization experience accumulated by the COVID-19 vaccine would help a group of outstanding domestic Chinese vaccine company's snowball. Against this backdrop, the Chinese vaccine industry is expected to usher in a golden period. The next decade will be for China's biopharmaceuticals to move from catching up to surpassing a 'golden decade' for the Chinese vaccine industry.

May 2022, Walvax Biotechnology Co., Ltd. announced the results for the immunogenicity and safety profile of PCV13, the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, administered as an infant series at 3, 4, and 5 months of age and a booster dose at 12-15 months of age in Chinese infants as part of the randomized, multi-center, double-blind, and positive-controlled phase 3 clinical trial in China to demonstrate the non-inferior immune responses and safety of PCV13 as compared to Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein] ('PCV7').

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities

5. China Vaccine Market
5.1 Public
5.2 Private

6. China Vaccine Doses
6.1 Public
6.2 Private

7. China Vaccine Share Analysis
7.1 By Sectors Market Share
7.2 By Sectors Vaccine Doses Share
7.3 By Products Type Market Share
7.4 By Disease Type Market Share

8. Meningococcal Meningitis Vaccine Market & Doses Analysis
8.1 Meningococcal Meningitis Vaccine
8.1.1 Public
8.1.2 Private
8.2 Meningococcal Meningitis Doses
8.2.1 Public
8.2.2 Private

9. Pneumococcal Vaccines Market & Doses Analysis
9.1 Pneumococcal Vaccines
9.2 Pneumococcal Vaccines Doses

10. DTP Vaccine Market & Doses Analysis
10.1 DTP Vaccine Market
10.1.1 DTaP
10.1.2 DTcP
10.2 DTP Vaccine Doses
10.2.1 Public
10.2.2 Private

11. Rabies Vaccine Market

12. Ebola Vaccine Market

13. Product - China Vaccine Market
13.1 MCV4
13.2 MPSV4
13.3 MCV2-Hib
13.4 MCV2
13.5 MPSV2 and Men A
13.6 PCV13
13.7 PPV23
13.8 Others

14. The Vaccine Regulatory Authority of China

15. Required and Recommended Vaccinations for China Travel

16. Mergers & Acquisitions

17. Company Sales
17.1 Sinopharm Group (China National Biotec Group Company Limited)
17.1.1 Overview
17.1.2 Recent Initiatives
17.1.3 Net Sales
17.2 Hualan Biological Engineering Inc
17.2.1 Overview
17.2.2 Recent Initiatives
17.2.3 Net Sales
17.3 Chongqing Zhifei Biological Products Co Ltd
17.3.1 Overview
17.3.2 Recent Initiatives
17.3.3 Net Sales
17.4 Walvax Biotechnology Co Ltd
17.4.1 Overview
17.4.2 Recent Initiatives
17.4.3 Net Sales
17.5 Beijing Tiantan Biological Products Corp Ltd
17.5.1 Overview
17.5.2 Recent Initiatives
17.5.3 Net Sales
17.6 Sinovac Biotech
17.6.1 Overview
17.6.2 Recent Initiatives
17.6.3 Net Sales
17.7 Shenzhen Kangtai Biological Products Co Ltd
17.7.1 Overview
17.7.2 Recent Initiatives
17.7.3 Net Sales

For more information about this report visit https://www.researchandmarkets.com/r/6cm1uw-vaccine?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets